rhodamine 123 has been researched along with deoxycytidine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dong, P; Jiang, AC; Li, L; Wan, Y; Yu, ZW | 1 |
Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C | 1 |
2 other study(ies) available for rhodamine 123 and deoxycytidine
Article | Year |
---|---|
The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Dyes; Fluorouracil; Gemcitabine; Humans; Laryngeal Neoplasms; Multidrug Resistance-Associated Proteins; Paclitaxel; Rhodamine 123 | 2007 |
Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Capecitabine; Carcinoma, Hepatocellular; Cell Line; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorescent Dyes; Fluorouracil; Glycoproteins; Hep G2 Cells; Humans; Immunohistochemistry; Interferon-alpha; Liver Neoplasms; Oxides; Peptides; Rhodamine 123; Thy-1 Antigens | 2011 |